Lilly’s Kisunla: Labeling Allows For Stopping Treatment Based On Amyloid Plaque Reduction
Executive Summary
However, the US FDA’s approval of donanemab comes with little guidance on when to stop treatment or when the anti-amyloid agent may need to be restarted in Alzheimer’s patients.